Sinopharm Group Statistics
Total Valuation
Sinopharm Group has a market cap or net worth of 8.43 billion. The enterprise value is 21.63 billion.
| Market Cap | 8.43B |
| Enterprise Value | 21.63B |
Important Dates
The next estimated earnings date is Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | Jun 16, 2025 |
Share Statistics
| Current Share Class | 1.34B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.36% |
| Shares Change (QoQ) | -82.11% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 27.04% |
| Float | 1.34B |
Valuation Ratios
The trailing PE ratio is 8.48 and the forward PE ratio is 7.52.
| PE Ratio | 8.48 |
| Forward PE | 7.52 |
| PS Ratio | 0.10 |
| PB Ratio | 0.45 |
| P/TBV Ratio | 0.83 |
| P/FCF Ratio | 3.17 |
| P/OCF Ratio | 2.97 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.67, with an EV/FCF ratio of 8.12.
| EV / Earnings | 21.76 |
| EV / Sales | 0.27 |
| EV / EBITDA | 6.67 |
| EV / EBIT | 8.31 |
| EV / FCF | 8.12 |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.63.
| Current Ratio | 1.35 |
| Quick Ratio | 1.07 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 3.79 |
| Debt / FCF | 4.39 |
| Interest Coverage | 6.31 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 7.13% |
| Return on Capital Employed (ROCE) | 12.24% |
| Weighted Average Cost of Capital (WACC) | 4.62% |
| Revenue Per Employee | 744,483 |
| Profits Per Employee | 9,187 |
| Employee Count | 108,217 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Sinopharm Group has paid 549.07 million in taxes.
| Income Tax | 549.07M |
| Effective Tax Rate | 27.83% |
Stock Price Statistics
The stock price has decreased by -5.62% in the last 52 weeks. The beta is 0.63, so Sinopharm Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | -5.62% |
| 50-Day Moving Average | 2.41 |
| 200-Day Moving Average | 2.67 |
| Relative Strength Index (RSI) | 47.98 |
| Average Volume (20 Days) | 1,025 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sinopharm Group had revenue of 80.57 billion and earned 994.19 million in profits. Earnings per share was 0.32.
| Revenue | 80.57B |
| Gross Profit | 5.96B |
| Operating Income | 2.45B |
| Pretax Income | 1.97B |
| Net Income | 994.19M |
| EBITDA | 2.75B |
| EBIT | 2.45B |
| Earnings Per Share (EPS) | 0.32 |
Balance Sheet
The company has 5.45 billion in cash and 11.70 billion in debt, with a net cash position of -6.25 billion.
| Cash & Cash Equivalents | 5.45B |
| Total Debt | 11.70B |
| Net Cash | -6.25B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 18.57B |
| Book Value Per Share | 3.70 |
| Working Capital | 13.48B |
Cash Flow
In the last 12 months, operating cash flow was 2.84 billion and capital expenditures -171.97 million, giving a free cash flow of 2.66 billion.
| Operating Cash Flow | 2.84B |
| Capital Expenditures | -171.97M |
| Free Cash Flow | 2.66B |
| FCF Per Share | n/a |
Margins
Gross margin is 7.40%, with operating and profit margins of 3.04% and 1.23%.
| Gross Margin | 7.40% |
| Operating Margin | 3.04% |
| Pretax Margin | 2.45% |
| Profit Margin | 1.23% |
| EBITDA Margin | 3.42% |
| EBIT Margin | 3.04% |
| FCF Margin | 3.31% |
Dividends & Yields
This stock pays an annual dividend of 0.09, which amounts to a dividend yield of 4.01%.
| Dividend Per Share | 0.09 |
| Dividend Yield | 4.01% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 10.73% |
| Buyback Yield | 0.36% |
| Shareholder Yield | 4.36% |
| Earnings Yield | 11.79% |
| FCF Yield | 31.59% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sinopharm Group has an Altman Z-Score of 2.1 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.1 |
| Piotroski F-Score | 3 |